A robust segmental performance is likely to have benefited RSG's top line in the fourth quarter of 2024.

HubSpot is expected to record top-line growth in the fourth quarter, driven by healthy demand trends and AI focus.

MCD's fourth-quarter 2024 top line is likely to have been aided by strong digital adoption, innovative menu additions and unit expansion.

PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the fourth quarter.

CROX's fourth-quarter 2024 top-line results are likely to reflect gains from solid consumer demand and strength in clogs, sandals and personalization.

IQV's top line in the fourth quarter of 2024 is expected to have benefited from the rising use of GenAI to provide crucial insights.

PEGA's fourth-quarter 2024 results are likely to benefit from increased adoption of GenAI Blueprint tool and Pega Cloud platform.

ODFL's fourth-quarter 2024 top line is expected to have suffered from the freight market downturn and economic uncertainties.

NVS' key drugs, Entresto, Cosentyx Kisqali and Pluvicto, are likely to have fueled its top and bottom-line performance in the fourth quarter.

GEHC's fourth-quarter results are likely to reflect mixed segmental performance in imaging, advanced visualization solutions and patient care. Pharma...